Safinamide as a Valuable Add-on Therapy – Exploring New Approaches to Parkinson’s Disease Management Through Patient Case Presentations
Alain Kaelin, Jaime Kulisevsky, Heinz Reichmann
Introduction Safinamide is an innovative therapeutic option in Parkinson’s disease (PD), with a unique dual mode of action that goes beyond dopaminergic pathways.1 Its mechanisms of action include monoamine oxidase-B (MAO-B) and dopamine reuptake inhibition, activity-dependent sodium-channel inhibition, and inhibition of glutamate release.2 In pivotal clinical trials, safinamide used as add-on to levodopa, demonstrated efficacy […]